MA27504A1 - Proteine cytotoxique et son utilisation - Google Patents

Proteine cytotoxique et son utilisation

Info

Publication number
MA27504A1
MA27504A1 MA27761A MA27761A MA27504A1 MA 27504 A1 MA27504 A1 MA 27504A1 MA 27761 A MA27761 A MA 27761A MA 27761 A MA27761 A MA 27761A MA 27504 A1 MA27504 A1 MA 27504A1
Authority
MA
Morocco
Prior art keywords
protein
toxin
cytotoxic protein
produced
cytotoxic
Prior art date
Application number
MA27761A
Other languages
English (en)
Inventor
Hiroyuki Ohno
Hideki Tanzawa
Hiromitsu Saisho
Original Assignee
Hiroyuki Ohno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroyuki Ohno filed Critical Hiroyuki Ohno
Publication of MA27504A1 publication Critical patent/MA27504A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PROT„„ÉINE CYTOTOXIQUE ET SON UTILISATION Cette invention concerne une nouvelle protéine cytotoxique (toxine M, toxine causant la détérioration de la membrane muqueuse) produite par Helicobacter pyroli, et l'utilisation de cette protéine. Cette invention fournit une protéine cytotoxique (toxine M) produite par Helicobacter pyroli , un peptide partiel, et un agent anti-tumeur contenant la protéine cytotoxique. La protéine est obtenue par la culture d'un transformant qui est transformé avec un vecteur de recombination contenant l'ADN codant la protéine cytotoxique. Cette invention fournit aussi l'usage de cette protéine.
MA27761A 2001-12-05 2004-07-05 Proteine cytotoxique et son utilisation MA27504A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001371210 2001-12-05

Publications (1)

Publication Number Publication Date
MA27504A1 true MA27504A1 (fr) 2005-09-01

Family

ID=19180288

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27761A MA27504A1 (fr) 2001-12-05 2004-07-05 Proteine cytotoxique et son utilisation

Country Status (25)

Country Link
US (3) US7385035B2 (fr)
EP (1) EP1462457B1 (fr)
JP (1) JP4776166B2 (fr)
KR (1) KR100628917B1 (fr)
CN (1) CN1599750B (fr)
AT (1) ATE393164T1 (fr)
AU (1) AU2002354096B2 (fr)
BR (1) BR0215114A (fr)
CA (1) CA2469154C (fr)
CO (1) CO5590932A2 (fr)
DE (1) DE60226277T2 (fr)
ES (1) ES2305323T3 (fr)
HR (1) HRP20040442A2 (fr)
IL (1) IL162320A0 (fr)
IS (1) IS7270A (fr)
MA (1) MA27504A1 (fr)
MX (1) MXPA04005459A (fr)
NO (1) NO20042130L (fr)
NZ (1) NZ533797A (fr)
PL (1) PL370704A1 (fr)
RS (1) RS49804A (fr)
RU (1) RU2004117155A (fr)
TW (1) TW200303919A (fr)
WO (1) WO2003048199A1 (fr)
ZA (1) ZA200404209B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004357586A (ja) * 2003-06-04 2004-12-24 Hiroyuki Ono 細胞障害タンパク質ｍ毒素の発現方法
WO2007072576A1 (fr) * 2005-12-21 2007-06-28 Fourier Inc. Procédé de production d'une souche capable d'exprimer en grande quantité une toxine m dérivée de helicobacter pylori
US8151835B2 (en) * 2006-08-23 2012-04-10 Fht, Inc. Automated drug delivery bag filling system
CN113567671A (zh) * 2020-04-29 2021-10-29 南京农业大学 猪血管紧张素转化酶2(ace2)多克隆抗体的制备

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218158A3 (fr) 1985-09-30 1988-12-07 Asahi Kasei Kogyo Kabushiki Kaisha Anticorps monoclonal humain, lignée de cellules B pour la production de cet anticorps et méthode de préparation de cette lignée de cellules B et de cet anticorps.
EP0232871A3 (fr) 1986-02-07 1989-03-15 Yoshitomi Pharmaceutical Industries, Ltd. Anticorps monoclonal humain, hybridome le produisant et son utilisation
JPH0798000B2 (ja) 1987-05-23 1995-10-25 萩原 義秀 ガン関連抗原特異的ヒト免疫グロブリン
US5366865A (en) 1989-04-06 1994-11-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-platelet monoclonal antibody
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
HUP0100267A3 (en) * 1996-03-29 2002-09-30 Astra Ab Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
KR20010031034A (ko) * 1997-10-09 2001-04-16 페리오 프로덕츠 리미티드 전체 방출을 지연시키는 위장의 약물 송달 시스템
JP2000063280A (ja) * 1998-06-11 2000-02-29 Takeda Chem Ind Ltd 抗ヘリコバクタ―・ピロリ活性胃腸薬
RU2227752C2 (ru) 1998-11-12 2004-04-27 Новолитикс Инк. Способы перекрытия кровотока и композиции для их реализации
EP1268774A2 (fr) * 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification de genes esentiels dans des procaryotes

Also Published As

Publication number Publication date
ES2305323T3 (es) 2008-11-01
RS49804A (en) 2006-10-27
CA2469154A1 (fr) 2003-06-12
US20090208972A1 (en) 2009-08-20
PL370704A1 (en) 2005-05-30
CA2469154C (fr) 2011-03-01
US20080233556A1 (en) 2008-09-25
DE60226277D1 (de) 2008-06-05
IL162320A0 (en) 2005-11-20
MXPA04005459A (es) 2004-10-11
TW200303919A (en) 2003-09-16
CN1599750B (zh) 2010-05-12
NZ533797A (en) 2008-07-31
DE60226277T2 (de) 2009-07-16
AU2002354096B2 (en) 2007-05-24
CO5590932A2 (es) 2005-12-30
RU2004117155A (ru) 2005-05-10
EP1462457B1 (fr) 2008-04-23
JP4776166B2 (ja) 2011-09-21
ZA200404209B (en) 2005-05-30
ATE393164T1 (de) 2008-05-15
WO2003048199A1 (fr) 2003-06-12
NO20042130L (no) 2004-09-01
BR0215114A (pt) 2005-02-01
AU2002354096A1 (en) 2003-06-17
JPWO2003048199A1 (ja) 2005-04-14
KR20050044708A (ko) 2005-05-12
US20060210575A1 (en) 2006-09-21
CN1599750A (zh) 2005-03-23
EP1462457A4 (fr) 2005-12-21
HRP20040442A2 (en) 2004-12-31
US7385035B2 (en) 2008-06-10
KR100628917B1 (ko) 2006-09-27
EP1462457A1 (fr) 2004-09-29
IS7270A (is) 2004-05-17

Similar Documents

Publication Publication Date Title
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
WO1996034107A3 (fr) Proteines antivirales, sequences d'adn codant pour ces proteines et utilisations
PL361700A1 (en) Methods of synthesizing an oxidant and applications thereof
DE69638117D1 (de) Varianten des menschlichen Wachstumshormons
ATE223488T1 (de) Gereinigte polyporus laccasen und dafür kodierende nukleinsäuren
WO2004033651A3 (fr) Erythropoietine: remodelage et glycoconjugaison d'erythropoietine
DK1379550T3 (da) Et kimært protein omfattende non-toxisk pseudomonas exotoxin A og en type IV pilin sekvenser
MA27504A1 (fr) Proteine cytotoxique et son utilisation
DK1379273T3 (da) Nukleinsyreadjuvanser
EP2305311A3 (fr) Glycoconjugation des peptides
ES2193014T3 (es) 3-metiloct-6-enoles 6-sustituidos.
DK1478659T3 (da) Biologisk aktive peptider
MXPA03008438A (es) Toxina insecticida de bacillus thuringiensis modificada sensible a pepsina.
SE0101519D0 (sv) Nucleic ACID
MXPA04000068A (es) Conjugados de progenipoyetina modificados quimicamente.
TR200003608T2 (tr) Moraxella Catarrhalis'e ait BASB027 proteinleri ve genleri.
ATE443715T1 (de) Polypeptide aus haemophilus influenza
ATE420962T1 (de) Rekombinante n-proteinase, deren herstellung, methoden und anwendungen
ATE274582T1 (de) Basb028 polypeptiden und dafür kodierende polynukleotiden aus moraxella catarrhalis
AU2003296543A1 (en) Peptides having a high cysteine content
GT200200277A (es) Cis-imidazolinas
DE60035788D1 (de) Polypeptide aus moraxella (branhamella) catarrhalis
WO2000046242A3 (fr) PROTEINE DE 19 KILODALTONS PRODUITE PAR LA BACTERIE $i(HELICOBACTER PYLORI)
ATE312494T1 (de) Verfahren zur aktivierung eines endgerätes